Dr. Salzman co-founded SwanBio Therapeutics, a gene therapy company, in 2017 and served as its CEO through 2019 and Head of Portfolio Development until the end of 2020. Before founding SwanBio, she served as Chief Science Officer at The Stop ALD Foundation, where she supported the world’s first non-HIV ex-vivo lentiviral gene therapy clinical trial. Dr. Salzman has been an active member and leader for over 20 years in the American Society of Gene & Cell Therapy (ASGCT) and member of the American Academy of Neurology’s Animal Science Rapid Response Team. Dr. Salzman received the Sonia Skarlatos Public Service Award in 2015 and was selected to be a Henri Termeer Fellow by the Termeer Foundation in 2021. She holds a DVM from Oklahoma State University College of Veterinary Medicine and a BS in animal science from Rutgers University.